Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626234 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
A Phase 1 study of cMET-dysregulated Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 15
- Study locations
NCT02626234: Completed Phase 1 study of cMET-dysregulated Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
NCT02626234 is a Phase 1 study of cMET-dysregulated Advanced Solid Tumors that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 15 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626234, a Phase 1 study of cMET-dysregulated Advanced Solid Tumors, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 15
- Study locations
Study Summary
the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
Primary Outcome
digoxin and rosuvastatin pharmacokinetics parameters
Conditions Studied
Interventions
- DRUG rosuvastatin
- DRUG INC280
- DRUG digoxin
Study Locations (15)
Other
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Brno
- Novartis Investigative Site - Athens
- Novartis Investigative Site - Bologna
- Novartis Investigative Site - Naples
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - London
- Novartis Investigative Site - Manchester
Georgia
- Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group - Atlanta
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Antwerpen
- Novartis Investigative Site - Edegem
GR
- Novartis Investigative Site - Ioannina
MI
- Novartis Investigative Site - Milan
TO
- Novartis Investigative Site - Candiolo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-12-08 |
| Est. Completion | 2017-04-28 |
| Phase | Phase 1 |
What the finished NCT02626234 record still lists
NCT02626234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with cMET-dysregulated Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which rosuvastatin is the first listed.
NCT02626234 lists 15 locations in 7 states (Other, Georgia, New Hampshire).
Frequently Asked Questions
What is clinical trial NCT02626234 about?
NCT02626234 is a clinical study titled "A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors". the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
What is the current status of trial NCT02626234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-12-08. Estimated completion is 2017-04-28.
What conditions does trial NCT02626234 study?
This clinical trial studies the following conditions: cMET-dysregulated Advanced Solid Tumors.
What interventions are being tested in trial NCT02626234?
The interventions under investigation include: rosuvastatin (DRUG), INC280 (DRUG), digoxin (DRUG).
Who is sponsoring clinical trial NCT02626234?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02626234 being conducted?
This trial has 15 study locations across Georgia, New Hampshire, Antwerpen, GR, MI. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02626234's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI